⌘K

Login Start Free

REGENERON PHARMACEUTICALS, INC.·4

Feb 26, 4:07 PM ET

SING GEORGE L 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 26, 2024

Insider Transaction Report

Form 4

Period: 2024-02-22

REGENERON PHARMACEUTICALS, INC.REGN

Director

Transactions

Sale
Common Stock
2024-02-22$960.00/sh−1,000$960,000→ 26,349 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-02-23−500→ 6,338 total
Exercise: $413.33Exp: 2025-01-02→ Common Stock (500 underlying)
Exercise/Conversion
Common Stock
2024-02-22$413.33/sh+1,000$413,330→ 27,349 total
Sale
Common Stock
2024-02-22$965.00/sh−1,000$965,000→ 26,349 total
Exercise/Conversion
Common Stock
2024-02-22$413.33/sh+1,000$413,330→ 27,349 total
Exercise/Conversion
Common Stock
2024-02-23$413.33/sh+500$206,665→ 26,849 total
Exercise/Conversion
Common Stock
2024-02-22$413.33/sh+1,000$413,330→ 27,349 total
Sale
Common Stock
2024-02-22$970.00/sh−1,000$970,000→ 26,349 total
Sale
Common Stock
2024-02-23$985.00/sh−500$492,500→ 26,349 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-02-22−3,000→ 6,838 total
Exercise: $413.33Exp: 2025-01-02→ Common Stock (3,000 underlying)

Holdings

Common Stock
(indirect: By Spouse)
400
Common Stock
(indirect: By Spouse)
750
Common Stock
(indirect: By Trust)
1,000

Footnotes (1)

[F1]The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT